Cholesterol
Has been registered,DMF 038440, CDEF20220000434
SINOPEG is serving pharmaceutical and medical device companies around the globe, with product presence in various pharmaceutical/device development pipeline (pre-clinical, clinical, and post authorization large scale supply). Our facility is ISO9001 and ISO13485 certified, and is operating according to ICH Q7A guidelines to produce products for pharmaceutical companies.
Please contact us at sales@sinopeg.com for PEG derivatives. Our online catalog or inventory may not listed or have all molecular weights and functional groups, which may be available by custom synthesis. Please contact us at sales@sinopeg.com for quotation and availability.
Custom synthesis & CMO services are available.
Reference:
1. Peng K, Zhao X, Li H, Fu YX, Liang Y. Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control. J Exp Med. 2025;222(9):e20241454. doi:10.1084/jem.20241454
2. Ye T, Zhou J, Guo C, et al. Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus. Cell Rep. 2024;43(6):114269. doi:10.1016/j.celrep.2024.114269
3. Cao H, Zhang X, Cheng J, et al. A QS21 + CpG-Adjuvanted Trivalent HSV-2 Vaccine and Trivalent HSV-2 mRNA Vaccine Induce a Strong Immune Response, Protect Against HSV-2 Infection, and Cross-Protect Against HSV-1 Infection in Mice. Vaccines (Basel). 2025;13(5):497. Published 2025 May 6. doi:10.3390/vaccines13050497
4. Zhang S, Wang X, Zhao T, Yang C, Huang L. Development and Evaluation of the Immunogenic Potential of an Unmodified Nucleoside mRNA Vaccine for Herpes Zoster. Vaccines (Basel). 2025;13(1):68. Published 2025 Jan 13. doi:10.3390/vaccines13010068
5. Wang Z, Tian C, Zhu J, et al. Avian influenza mRNA vaccine encoding hemagglutinin provides complete protection against divergent H5N1 viruses in specific-pathogen-free chickens. J Nanobiotechnology. 2025;23(1):55. Published 2025 Jan 29. doi:10.1186/s12951-025-03156-w
6. Xiao C, Liu X, Liu P, et al. Oncogenic roles of young human de novo genes and their potential as neoantigens in cancer immunotherapy. Cell Genom. 2025;5(9):100928. doi:10.1016/j.xgen.2025.100928
7. Yu W, Chen X, Chen Q, et al. A Safe and Broad-spectrum SARS-CoV-2 mRNA Vaccine with a New Delivery System for In-situ Expression. Virol Sin. Published online September 4, 2025. doi:10.1016/j.virs.2025.09.001
8. Wang R, Zhang Y, Du S, Li Y, Ren Y, Lin J. Nanoformulations Downregulating METTL16 Combined with mRNA Tumor Vaccines Suppress Triple-Negative Breast Cancer and Prevent Metastasis. Int J Nanomedicine. 2025;20:8951-8966. Published 2025 Jul 11. doi:10.2147/IJN.S520329
9. Li L, Luo M, Zhou L, et al. Glucocorticoid pre-administration improves LNP-mRNA mediated protein replacement and genome editing therapies. Int J Pharm. 2025;672:125282. doi:10.1016/j.ijpharm.2025.125282
10. Wu K, Xu F, Dai Y, et al. Characterization of mRNA-LNP structural features and mechanisms for enhanced mRNA vaccine immunogenicity. J Control Release. 2024;376:1288-1299. doi:10.1016/j.jconrel.2024.11.007
11. Wan J, Wang Z, Wang L, et al. Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses. mBio. 2024;15(1):e0177523. doi:10.1128/mbio.01775-23
12. Yu, Juntao & Li, Qian & Luo, Shenggen & Wang, Xiaona & Cheng, Qiang & hu, Rongkuan. (2024). Targeted LNPs deliver mRNA encoding IL-15 superagonists to balance efficacy and toxicity in cancer therapy. 10.1101/2024.01.11.575299.
13. Sun, Zhen & Liu, Yuxiao & Zhang, Haoyi & Ge, Ting & Pan, Yuting & Liu, Yang & Wu, Miaomiao & Shan, Tao & Wu, Qi & Zhu, Guoqiang & Chen, Kangming. (2025). Next-Generation saRNA Platforms: Systematic Screening and Engineering Enhances Superior Protein Expression and Organ-Specific Targeting for RNA Therapeutics. 10.1101/2025.03.30.644708.
14. Liu X, Li Z, Li X, et al. A single-dose circular RNA vaccine prevents Zika virus infection without enhancing dengue severity in mice. Nat Commun. 2024;15(1):8932. Published 2024 Oct 16. doi:10.1038/s41467-024-53242-0
15. Chen YC, Lee YL, Lee CA, Lin TY, Hwu EE, Cheng PC. Development of a Lipid-encapsulated TGFβRI-siRNA Drug for Liver Fibrosis Induced by Schistosoma mansoni. PLoS Negl Trop Dis. 2024;18(9):e0012502. Published 2024 Sep 12. doi:10.1371/journal.pntd.0012502
16. Wang L, Wan J, He W, et al. IL-7 promotes mRNA vaccine-induced long-term immunity. J Nanobiotechnology. 2024;22(1):716. Published 2024 Nov 16. doi:10.1186/s12951-024-02993-5
17. Bian X, Guo Q, Yau LF, et al. Berberine-inspired ionizable lipid for self-structure stabilization and brain targeting delivery of nucleic acid therapeutics. Nat Commun. 2025;16(1):2368. Published 2025 Mar 10. doi:10.1038/s41467-025-57488-0
18. Ma X, Liu S, Fan B, et al. Enhancing mRNA translation efficiency by introducing sequence optimized AU-rich elements in 3' UTR via HuR anchorage. Mol Ther Nucleic Acids. 2025;36(2):102485. Published 2025 Feb 12. doi:10.1016/j.omtn.2025.102485
19. Yufeng Zhang,Liuwei Zhang,Hui Gao, et al. Multi-functional lipid nanoformulations for enhancing the efficacy of mRNA tumor vaccines by reversing tumor immunosuppressive microenvironment[J].Nano Today, 2025, 63.DOI:10.1016/j.nantod.2025.102757.
20. Shao X, Liu L, Weng C, et al. Leveraging an mRNA Platform for the Development of Vaccines Against Egg Allergy. Vaccines (l). 2025;13(5):448. Published 2025 Apr 24. doi:10.3390/vaccines13050448
